Analysts Offer Insights on Healthcare Companies: Zafgen (NASDAQ: ZFGN) and Merrimack Pharmaceuticals (NASDAQ: MACK)

By Austin Angelo

Analysts fell to the sidelines weighing in on Zafgen (NASDAQ: ZFGN) and Merrimack Pharmaceuticals (NASDAQ: MACK) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.

Zafgen (NASDAQ: ZFGN)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Zafgen today. The company’s shares opened today at $7.40.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 16.4% and a 59.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Zafgen.

See today’s analyst top recommended stocks >>

Merrimack Pharmaceuticals (NASDAQ: MACK)

In a report released today, Marc Frahm from Cowen & Co. reiterated a Hold rating on Merrimack Pharmaceuticals. The company’s shares opened today at $6.15, close to its 52-week low of $5.55.

According to TipRanks.com, Frahm is ranked #3325 out of 4830 analysts.

The word on The Street in general, suggests a Hold analyst consensus rating for Merrimack Pharmaceuticals.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.